CL

Cellebrite DI Ltd.

CLBTTechnologyNASDAQ

Software - Infrastructure · Last scanned Jul 18, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$475.7M
+18.6% YoY
Net Income
$78.3M
+127.7% YoY
EBITDA
$103.1M
+138.8% YoY
Free Cash Flow
$149.6M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 RSI OverboughtRSI 78.3, above 70, stock may be overbought
Jul 10 RSI OverboughtRSI 82.3, above 70, stock may be overbought
About Cellebrite DI Ltd.

Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Valued at $3.85B, CLBT is a mid-cap name in its sector. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency.

Key stats
Market Cap$3.85B
P/E (TTM)57.19
Fwd P/E23.36
EPS$0.27
Beta1.17
52W Change+7.4%
ROE16.4%
Analysis

The balance sheet looks solid with $429.1M in cash comfortably exceeding the $22.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $149.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 16.4%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $270.7M (2022) to $475.7M (2025), reflecting a 76% increase over the period.

With cash comfortably exceeding debt, CLBT has financial flexibility that may help navigate uncertain periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cellebrite DI Ltd.'s trajectory.

Links
More Technology stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms